Kai He
Medical Oncology · Columbus, OHNPI 1114245420
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,513 of the $49,085 with a category attached, or 80.5%. E.r. Squibb & Sons, L.L.C. accounts for 69.8% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $25,122, more than ten times the $2,118 reported in 2019. Among medical oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $876.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$34K
- Biontech SE$4K
- Amgen$3K
- AstraZeneca$2K
- F. Hoffmann-la Roche AG$2K
- Pfizer$2K
- plus $3K from 10 others
Across 308 payments — averaging $35,115 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$7.7M
- Iovance Biotherapeutics, Inc.$929K
- AbbVie$903K
- Mirati Therapeutics, Inc.$412K
- E.r. Squibb & Sons, L.L.C.$338K
- Genentech, Inc.$287K
- plus $263K from 5 others
What the payments were for
- Consulting fees$39,51380%
- Speaking & faculty fees$3,3477%
- Travel & lodging$3,8238%
- Food & beverage$2,4025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 31 | $34,241 |
| Biontech SE | 2 | $3,721 |
| Amgen | 2 | $2,744 |
| AstraZeneca | 1 | $2,398 |
| F. Hoffmann-la Roche AG | 2 | $1,907 |
| Pfizer | 2 | $1,556 |
| Johnson & Johnson | 3 | $1,484 |
| Genentech USA, Inc. | 4 | $227 |
| Galvanize Therapeutics, Inc | 1 | $161 |
| Genentech, Inc. | 2 | $144 |
| Beigene USA, Inc. | 1 | $129 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Jazz Pharmaceuticals Inc. | 1 | $75 |
| Novartis | 1 | $74 |
| Janssen Scientific Affairs, LLC | 1 | $67 |
| Servier Bioinnovation | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,085 in reported general payments places this provider in the 90th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Columbus
- David CarboneColumbus$438K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Timothy BurnsColumbus$64K
- Gregory OttersonColumbus$49K
- Sagar SardesaiColumbus$45K
- Asrar AlahmadiColumbus$36K
- John HaysColumbus$35K
- Claire VerschraegenColumbus$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.